Cited by 2,292Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record, with a small difference in title or year; 28 of the 28 references it cites were found in a registry or an index.

C-Reactive Protein Levels and Outcomes after Statin Therapy

Open access

Ridker, Paul M, Cannon, Christopher P., Morrow, David, Rifai, Nader, Rose, Lynda M., McCabe, Carolyn H., Pfeffer, Marc A., Braunwald, Eugene·2005·New England Journal of Medicine

DOI 10.1056/nejmoa042378

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Statins lower the levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP). Whether this latter property affects clinical outcomes is unknown. METHODS: We evaluated relationships between the LDL cholesterol and CRP levels achieved after treatment with 80 mg of atorvastatin or 40 mg of pravastatin per day and the risk of recurrent myocardial infarction or death from coronary causes among 3745 patients with acute coronary syndromes. RESULTS: Patients in whom statin therapy resulted in LDL cholesterol levels of less than 70 mg per deciliter (1.8 mmol per liter) had lower event rates than those with higher levels (2.7 vs. 4.0 events per 100 person-years, P=0.008). However, a virtually identical difference was observed between those who had CRP levels of less than 2 mg per liter after statin therapy and those who had higher levels (2.8 vs. 3.9 events per 100 person-years, P=0.006), an effect present at all levels of LDL cholesterol achieved. For patients with post-treatment LDL cholesterol levels of more than 70 mg per deciliter, the rates of recurrent events were 4.6 per 100 person-years among those with CRP levels of more than 2 mg per liter and 3.2 events per 100 person-years among those with CRP levels of less than 2 mg per liter; the respective rates among those with LDL cholesterol levels of less than 70 mg per deciliter were 3.1 and 2.4 events per 100 person-years (P<0.001). Although atorvastatin was more likely than pravastatin to result in low levels of LDL cholesterol and CRP, meeting these targets was more important in determining the outcomes than was the specific choice of therapy. Patients who had LDL cholesterol levels of less than 70 mg per deciliter and CRP levels of less than 1 mg per liter after statin therapy had the lowest rate of recurrent events (1.9 per 100 person-years). CONCLUSIONS: Patients who have low CRP levels after statin therapy have better clinical outcomes than those with higher CRP levels, regardless of the resultant level of LDL cholesterol. Strategies to lower cardiovascular risk with statins should include monitoring CRP as well as cholesterol.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa042378

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citation
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citation
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Self-citation
C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina
Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. L., Rebuzzi, A. G., Pepys, M. B., & Maseri, A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408183310701 · Cited by 2,354
Effect of Statin Therapy on C-Reactive Protein Levels
Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators (2001) · JAMA · doi:10.1001/jama.286.1.64 · Cited by 1,644
Self-citation
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Self-citation

Flagged first, then by citations

Show all 28 references

Research works printed but not linked: 1

Davignon J, 2004, Circulation, 109, III

Sorted by citations

Items 201–300 of 1,000

Effects of Weight Loss and Long-Term Weight Maintenance With Diets Varying in Protein and Glycemic Index on Cardiovascular Risk Factors: The Diet, Obesity, and Genes (DiOGenes) Study: A Randomized, Controlled Trial
Gögebakan, Ö., Kohl, A., Osterhoff, M. A., van Baak, M. A., Jebb, S. A., Papadaki, A., Martinez, J. A., Handjieva-Darlenska, T., Hlavaty, P., Weickert, M. O., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.033274 · Cited by 180
Effects of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Fluvastatin, on Coronary Spasm After Withdrawal of Calcium-Channel Blockers
Yasue, H., Mizuno, Y., Harada, E., Itoh, T., Nakagawa, H., Nakayama, M., Ogawa, H., Tayama, S., Honda, T., Hokimoto, S., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.12.049 · Cited by 178
Using Nontraditional Risk Factors in Coronary Heart Disease Risk Assessment: U.S. Preventive Services Task Force Recommendation Statement
U.S. Preventive Services Task Force* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-7-200910060-00008 · Cited by 180
Potential therapeutic role for statins in respiratory disease
Hothersall, E. J. (2006) · Thorax · doi:10.1136/thx.2005.057976 · Cited by 178
Overview of hemostatic factors involved in atherosclerotic cardiovascular disease
Kannel, W. B. (2005) · Lipids · doi:10.1007/s11745-005-1488-8 · Cited by 177
C-Reactive Protein and Prediction of 1-Year Mortality in Prevalent Hemodialysis Patients
Bazeley, J. W., Bieber, B. A., Li, Y., Morgenstern, H., de Sequera, P., Combe, C., Yamamoto, H., Gallagher, M., Port, F. K., & Robinson, B. M. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00710111 · Cited by 178
Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk
Ridker, P. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.082 · Cited by 186
Self-citation
Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure: A Systematic Review
Araújo, J. P., Lourenço, P., Azevedo, A., Friões, F., Rocha‐Gonçalves, F., Ferreira, A., & Bettencourt, P. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.10.030 · Cited by 177
Augmentation of Myocardial Production of 15-Epi-Lipoxin-A 4 by Pioglitazone and Atorvastatin in the Rat
Birnbaum, Y., Ye, Y., Lin, Y., Freeberg, S. Y., Nishi, S. P. E., Martinez, J. D., Huang, M.-H., Uretsky, B. F., & Perez-Polo, J. R. (2006) · Circulation · doi:10.1161/circulationaha.106.629907 · Cited by 172
Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease
Aday, A. W., & Ridker, P. M. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00016 · Cited by 178
Self-citation
Targeting the CCL2–CCR2 axis for atheroprotection
Georgakis, M. K., Bernhagen, J., Heitman, L. H., Weber, C., & Dichgans, M. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac094 · Cited by 182
Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN
Puri, R., Libby, P., Nissen, S. E., Wolski, K., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R., Raichlen, J. S., Uno, K., et al. (2014) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jet251 · Cited by 174
C-Reactive Protein and High-Sensitivity C-Reactive Protein: An Update for Clinicians
Windgassen, E. B., Funtowicz, L., Lunsford, T. N., Harris, L. A., & Mulvagh, S. L. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.01.2252 · Cited by 170
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease
Yeganeh, B., Wiecheć, E., Ande, S. R., Sharma, P. K., Moghadam, A. R., Post, M., Freed, D. H., Hashemi, M. M., Shojaei, S., Zeki, A. A., et al. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.02.007 · Cited by 169
The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction
Hennessy, T., Soh, L., Bowman, M. H., Kurup, R., Schultz, C. J., Patel, S., & Hillis, G. S. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.06.003 · Cited by 176
Cardioprotective Medication Is Associated With Improved Survival in Patients With Peripheral Arterial Disease
Feringa, H. H. H., van Waning, V. H., Bax, J. J., Elhendy, A., Boersma, E. H., Schouten, O., Galal, W., Vidaković, R., Tangelder, M. J. D., & Poldermans, D. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.09.074 · Cited by 172
Rosuvastatin in the Prevention of Stroke Among Men and Women With Elevated Levels of C-Reactive Protein
Everett, B. M., Glynn, R. J., MacFadyen, J. G., & Ridker, P. M. (2009) · Circulation · doi:10.1161/circulationaha.109.874834 · Cited by 168
Self-citation
Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies
Klingenberg, R., & Hansson, G. K. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp477 · Cited by 171
Association of statin prescription with small abdominal aortic aneurysm progression
Ferguson, C. D., Clancy, P., Bourke, B. M., Walker, P. J., Dear, A. E., Buckenham, T. M., Norman, P. E., & Golledge, J. (2010) · American Heart Journal · doi:10.1016/j.ahj.2009.11.016 · Cited by 169
Inflammation as a Therapeutic Target in Atherosclerosis
Nguyen, M. T., Fernando, S., Schwarz, N., Tan, J. T. M., Bursill, C. A., & Psaltis, P. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081109 · Cited by 176
The Biological Role of Inflammation in Atherosclerosis
Wong, B. W., Meredith, A., Lin, D., & McManus, B. M. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.06.023 · Cited by 168
High-Resolution Magnetic Resonance Imaging Enhanced With Superparamagnetic Nanoparticles Measures Macrophage Burden in Atherosclerosis
Morishige, K., Kacher, D. F., Libby, P., Josephson, L., Ganz, P., Weissleder, R., & Aikawa, M. (2010) · Circulation · doi:10.1161/circulationaha.109.891804 · Cited by 168
Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--A 1-year randomized control trial
Szeto, C., Chow, K. M., Lam, C. W.-K., Leung, C. B., Kwan, B. C., Chung, K.-Y., Law, M.-C., & Li, P. K.-T. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl559 · Cited by 168
Growth Differentiation Factor-15 and Risk of Recurrent Events in Patients Stabilized After Acute Coronary Syndrome
Bonaca, M. P., Morrow, D. A., Braunwald, E., Cannon, C. P., Jiang, S., Breher, S., Sabatine, M. S., Kempf, T., Wallentin, L. C., & Wollert, K. C. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.213512 · Cited by 167
Self-citation
C-Reactive Protein in Atherosclerotic Lesions
Sun, H., Koike, T., Ichikawa, T., Hatakeyama, K., Shiomi, M., Zhang, B., Kitajima, S., Morimoto, M., Watanabe, T., Asada, Y., et al. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61202-3 · Cited by 166
Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Theraphy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial
Morrow, D. A., Wang, Y., Croce, K., Sakuma, M., Sabatine, M. S., Gao, H., Pradhan, A. D., Healy, A. M., Buros, J., McCabe, C. H., et al. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.08.018 · Cited by 168
Self-citation
Narrative Review: Lack of Evidence for Recommended Low-Density Lipoprotein Treatment Targets: A Solvable Problem
Hayward, R. A., Hofer, T. P., & Vijan, S. S. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-7-200610030-00010 · Cited by 163
C-reactive protein: a new risk assessment tool for cardiovascular disease.
Clearfield, M. B. (2005) · PubMed · Cited by 160
Biomarkers of abdominal aortic aneurysm progression. Part 2: inflammation
Hellenthal, F. A. M. V. I., Buurman, W. A., Wodzig, W. K. W. H., & Schurink, G. W. H. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.102 · Cited by 168
Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)
McMurray, J. J. V., KJEKSHUS, J. K., Gullestad, L. L., Dunselman, P., Hjalmarson, Å. C., Wedel, H., Lindberg, M., Waagstein, F., Grande, P., Hradec, J., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.849117 · Cited by 162
Inflammation and the Development of Atherosclerosis
Mizuno, Y., Jacob, R. F., & Mason, R. P. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.7591 · Cited by 166
Vascular Biomarkers and Surrogates in Cardiovascular Disease
Tardif, J., Heinonen, T. M., Orloff, D. G., & Libby, P. (2006) · Circulation · doi:10.1161/circulationaha.105.598987 · Cited by 159
Surprises from genetic analyses of lipid risk factors for atherosclerosis
Musunuru, K., & Kathiresan, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306398 · Cited by 159
Relation of Baseline High-Sensitivity C-Reactive Protein Level to Cardiovascular Outcomes With Rosuvastatin in the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)
Ridker, P. M., MacFadyen, J. G., Libby, P., & Glynn, R. J. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.03.018 · Cited by 159
Self-citation
Vascular endothelium dysfunction: a conservative target in metabolic disorders
Jamwal, S., & Sharma, S. (2018) · Inflammation Research · doi:10.1007/s00011-018-1129-8 · Cited by 161
Nanoparticle-Enhanced Plasmonic Biosensor for Digital Biomarker Detection in a Microarray
Belushkin, A. A., Yesilköy, F., & Altug, H. (2018) · ACS Nano · doi:10.1021/acsnano.8b00519 · Cited by 159
Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein
Hanefeld, M., Marx, N., Pfützner, A., Baurecht, W., Lübben, G., Karagiannis, E., Stier, U., & Forst, T. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.08.054 · Cited by 161
C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study
Heart Protection Study Collaborative Group (2011) · The Lancet · doi:10.1016/s0140-6736(10)62174-5 · Cited by 159
Redox regulation of cardiovascular inflammation – Immunomodulatory function of mitochondrial and Nox-derived reactive oxygen and nitrogen species
Wenzel, P., Kossmann, S., Münzel, T. F., & Daiber, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.027 · Cited by 161
Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease
Luvai, A., Mbagaya, W., Hall, A. S., & Barth, J. H. (2012) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s4324 · Cited by 170
Consensus Panel Recommendation for Incorporating Lipoprotein-Associated Phospholipase A2 Testing into Cardiovascular Disease Risk Assessment Guidelines
Davidson, M. H., Corson, M. A., Alberts, M. J., Anderson, J. L., Gorelick, P. B., Jones, P. H., Lerman, A., McConnell, J. P., & WEINTRAUB, H. S. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.04.019 · Cited by 155
Treatment With 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients With Recent Acute Coronary Syndrome
Tardif, J., L’Allier, P. L., Ibrahim, R., Grégoire, J. C., Nozza, A., Cossette, M., Kouz, S., Lavoie, M.-A., Paquin, J., Brotz, T. M., et al. (2010) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.110.937169 · Cited by 161
Impact of Short-Term Administration of High-Density Lipoproteins and Atorvastatin on Atherosclerosis in Rabbits
Nicholls, S. J., Cutri, B., Worthley, S. G., Kee, P. H., Rye, K.-A., Bao, S., & Barter, P. J. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000184760.95957.d6 · Cited by 156
Determinants of Arterial Wall Remodeling During Lipid-Lowering Therapy
Schoenhagen, P., Tuzcu, E. M., Apperson-Hansen, C., Wang, C., Wolski, K., Lin, S., Sipahi, İ., Nicholls, S. J., Magyar, W. A., Loyd, A., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.585703 · Cited by 154
Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes
Ray, K. K., Cannon, C. P., Cairns, R., Morrow, D. A., Ridker, P. M., & Braunwald, E. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.181735 · Cited by 157
Self-citation
Predictors of Fatal and Non-Fatal Outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): Incremental Value of Apolipoprotein A-1, High-Sensitivity C-Reactive Peptide and N-terminal pro B-type Natriuretic Peptide
Wedel, H., McMurray, J. J. V., Lindberg, M., Wikstrand, J., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Hjalmarson, Å. C., KJEKSHUS, J. K., Michel Komajda, N., et al. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfn046 · Cited by 153
Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions
Kalkman, D. N., Aquino, M. B., Claessen, B. E. P. M., Baber, U., Guedeney, P., Sorrentino, S., Vogel, B., de Winter, R. J., Sweeny, J. M., Kovacic, J. C., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy633 · Cited by 160
The use of high-sensitivity assays for C-reactive protein in clinical practice
Musunuru, K., Kral, B. G., Blumenthal, R. S., Fuster, V., Campbell, C. Y., Gluckman, T. J., Lange, R. A., Topol, E. J., Willerson, J. T., Desai, M. Y., et al. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1322 · Cited by 160
Positive psychological attributes and cardiac outcomes: associations, mechanisms, and interventions
DuBois, C. M., Beach, S. R., Kashdan, T. B., Nyer, M. B., Park, E. R., Celano, C. M., & Huffman, J. C. (2012) · Psychosomatics · doi:10.1016/j.psym.2012.04.004 · Cited by 152
Polymorphism in KIF6 Gene and Benefit From Statins After Acute Coronary Syndromes
Iakoubova, O. A., Sabatine, M. S., Rowland, C. M., Tong, C. H., Catanese, J. J., Ranade, K., Simonsen, K. L., Kirchgessner, T. G., Cannon, C. P., Devlin, J. J., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.017 · Cited by 150
Self-citation
Effects of red orange juice intake on endothelial function and inflammatory markers in adult subjects with increased cardiovascular risk
Buscemi, S., Rosafio, G., Arcoleo, G., Mattina, A., Canino, B., Montana, M., Verga, S., & Rini, G. (2012) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.031088 · Cited by 151
Impact of Gut Microbiota and Diet on the Development of Atherosclerosis in Apoe −/− Mice
Jonsson, A. L., Caesar, R., Akrami, R., Reinhardt, C., Hållenius, F. F., Borén, J., & Bäckhed, F. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311233 · Cited by 157
Effect of high-dose α-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery diseasew
Devaraj, S., Tang, R., ADAMS-HUET, B. A., Harris, A., Seenivasan, T., de Lemos, J. A., & Jialal, I. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.5.1392 · Cited by 150
Relationship Between Cardiovascular Risk Factors and Atherosclerotic Disease Burden Measured by Intravascular Ultrasound
Nicholls, S. J., Tuzcu, E. M., Crowe, T., Sipahi, İ., Schoenhagen, P., Kapadia, S. R., Hazen, S. L., Wun, C., Norton, M., Ntanios, F. Y., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.12.058 · Cited by 150
Intermolecular Differences of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Contribute to Distinct Pharmacologic and Pleiotropic Actions
Mason, R. P., Walter, M. F., Day, C. A., & Jacob, R. F. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.008 · Cited by 153
Statins as antiinflammatory and immunomodulatory agents: A future in rheumatologic therapy?
Abeles, A. M., & Pillinger, M. H. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21521 · Cited by 151
Cytokines and cardiovascular disease
Mehra, V. C., Ramgolam, V. S., & Bender, J. R. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0405182 · Cited by 149
Immune Cells Mimic the Morphology of Endothelial Progenitor Colonies In Vitro
Rohde, E., Bartmann, C., Schallmoser, K., Reinisch, A., Lanzer, G., Linkesch, W., Guelly, C., & Strunk, D. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0833 · Cited by 152
Combined Therapy with Atorvastatin and Calcineurin Inhibitors: No Interactions with Tacrolimus
Lemahieu, W. P. D., Hermann, M., Åsberg, A., Verbeke, K., Holdaas, H., Vanrenterghem, Y. F. C., & Maes, B. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01005.x · Cited by 149
Genetic Variation Is Associated With C-Reactive Protein Levels in the Third National Health and Nutrition Examination Survey
Crawford, D. C., Sanders, C., Qin, X., Smith, J. D., Shephard, C., Wong, M., Witrak, L., Rieder, M. J., & Nickerson, D. A. (2006) · Circulation · doi:10.1161/circulationaha.106.615740 · Cited by 150
Cholesterol reduction yields clinical benefits: meta-analysis including recent trials
Gould, A. L., Davies, G., Alemao, E., Yin, D., & Cook, J. R. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.05.012 · Cited by 147
The JUPITER Trial
Ridker, P. M. (2009) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.109.868299 · Cited by 148
Self-citation
Atherosclerotic Plaque Stability—What Determines the Fate of a Plaque?
Halvorsen, B. L., Otterdal, K., Dahl, T. B., Skjelland, M., Gullestad, L. L., Øie, E., & Aukrust, P. (2008) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2008.09.001 · Cited by 146
Ezetimibe: cholesterol lowering and beyond
Bays, H. E., Neff, D., Tomassini, J. E., & Tershakovec, A. M. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.4.447 · Cited by 147
Valsartan, Blood Pressure Reduction, and C-Reactive Protein
Ridker, P. M., Danielson, E., Rifai, N., & Glynn, R. J. (2006) · Hypertension · doi:10.1161/01.hyp.0000226046.58883.32 · Cited by 148
Self-citation
The Association Between Reduction in Inflammation and Changes in Lipoprotein Levels and HDL Cholesterol Efflux Capacity in Rheumatoid Arthritis
Liao, K. P., Playford, M. P., Frits, M. L., Coblyn, J. S., Iannaccone, C. K., Weinblatt, M. E., Shadick, N. A., & Mehta, N. N. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001588 · Cited by 148
Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery
Owens, C. D., Ridker, P. M., Belkin, M., Hamdan, A. D., Pomposelli, F. B., LoGerfo, F. W., Creager, M. A., & Conte, M. S. (2006) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2006.08.048 · Cited by 145
Self-citation
Atorvastatin and Low-Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus Patients on Hemodialysis
März, W., Genser, B., Drechsler, C., Krane, V., Grammer, T. B., Ritz, E., Stojaković, T., Scharnagl, H., Winkler, K., Holme, I., et al. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09121010 · Cited by 146
Role of Lipotoxicity in Endothelial Dysfunction
Kim, J., Montagnani, M., Chandrasekran, S., & Quon, M. J. (2012) · Heart Failure Clinics · doi:10.1016/j.hfc.2012.06.012 · Cited by 153
Peripheral Arterial Disease: Diagnosis and Management
Arain, F. A., & Cooper, L. T. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.8.944 · Cited by 146
Usefulness of C-Reactive Protein and Interleukin-6 as Predictors of Outcomes in Patients With Chronic Obstructive Pulmonary Disease Receiving Pravastatin
Lee, T., Lin, M., & Chang, N. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.09.102 · Cited by 144
Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation
Aulin, J., Siegbahn, A. G., Hijazi, Z., Ezekowitz, M. D., Andersson, U., Connolly, S. J., Huber, K., Reilly, P. A., Wallentin, L. C., & Oldgren, J. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.09.018 · Cited by 144
Effect of Evolocumab on Coronary Plaque Composition
Nicholls, S. J., Puri, R., Anderson, T. J., Ballantyne, C. M., Cho, L., Kastelein, J. J. P., Köenig, W., Somaratne, R. M., Kassahun, H., Yang, J., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.078 · Cited by 146
Metabolic syndrome, inflammation and atherosclerosis
Paoletti, R., Bolego, C., Poli, A., & Cignarella, A. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.2.145 · Cited by 147
Statins inhibit Rho kinase activity in patients with atherosclerosis
Nohria, A., Pršić, A., Liu, P., Okamoto, R., Creager, M. A., Selwyn, A. P., Liao, J. K., & Ganz, P. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.12.023 · Cited by 143
Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials
Afilalo, J., Majdan, A. A., & Eisenberg, M. J. (2007) · Heart · doi:10.1136/hrt.2006.112508 · Cited by 143
Inflammatory and non-invasive vascular markers: The multimarker approach for risk stratification in coronary artery disease
Ikonomidis, I., Stamatelopoulos, K. S., Lekakis, J. P., Vamvakou, G. D., & Kremastinos, D. T. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.02.019 · Cited by 141
The Reduction of Inflammatory Biomarkers by Statin, Fibrate, and Combination Therapy Among Diabetic Patients With Mixed Dyslipidemia
Muhlestein, J. B., May, H. T., Jensen, J. R., Horne, B. D., Lanman, R. B., Lavasani, F., Wolfert, R. L., Pearson, R. R., Yannicelli, H. D., & Anderson, J. L. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.009 · Cited by 140
Statins for Atherosclerosis — As Good as It Gets?
Ehrenstein, M. R., Jury, E. C., & Mauri, C. (2005) · New England Journal of Medicine · doi:10.1056/nejme048326 · Cited by 138
Clinical implications for statin pleiotropy
Liao, J. K. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000191913.16321.60 · Cited by 139
Cytokine Biomarkers, Endothelial Inflammation, and Atherosclerosis in the Metabolic Syndrome: Emerging Concepts
Rizvi, A. A. (2009) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181a4158c · Cited by 138
Lipids, Lipoproteins, Apolipoproteins, and Other Cardiovascular Risk Factors
Remaley, A. T., Rifai, N., & Warnick, G. R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6164-9.00027-5 · Cited by 139
Self-citation
Vascular inflammation and low‐density lipoproteins: is cholesterol the link? A lesson from the clinical trials
Catapano, A. L., Pirillo, A., & Norata, G. D. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13805 · Cited by 138
The connection between C‐reactive protein and atherosclerosis
Singh, S. K., Suresh, M. V., Voleti, B., & Agrawal, A. C. (2008) · Annals of Medicine · doi:10.1080/07853890701749225 · Cited by 145
Effects of statins beyond lipid lowering: Potential for clinical benefits
Almuti, K., Rimawi, R., Spevack, D. M., & Ostfeld, R. J. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.05.056 · Cited by 139
Life course socioeconomic position is associated with inflammatory markers: The Framingham Offspring Study
Loucks, E. B., Pilote, L., Lynch, J. W., Richard, H., Almeida, N., Benjamin, E. J., & Murabito, J. M. (2010) · Social Science & Medicine · doi:10.1016/j.socscimed.2010.03.012 · Cited by 139
Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis
Libby, P. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r800099-jlr200 · Cited by 137
Long-Term Prognostic Value of Neopterin
Ray, K. K., Morrow, D. A., Sabatine, M. S., Shui, A. M., Rifai, N., Cannon, C. P., & Braunwald, E. (2007) · Circulation · doi:10.1161/circulationaha.106.666511 · Cited by 136
Self-citation
Electrochemical Immunosensor for Simultaneous Detection of Dual Cardiac Markers Based on a Poly(Dimethylsiloxane)-Gold Nanoparticles Composite Microfluidic Chip: A Proof of Principle
Zhou, F., Lu, M., Wang, W., Bian, Z., Zhang, J., & Zhu, J. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.147256 · Cited by 136
Relationship between markers of metabolic control and inflammation on severity of periodontal disease in patients with diabetes mellitus
Lim, L. P., Tay, F. B., Sum, C. F., & Thai, A. C. (2006) · Journal Of Clinical Periodontology · doi:10.1111/j.1600-051x.2006.01032.x · Cited by 136
The Endothelium and Inflammation
Trepels, T., Zeiher, A. M., & Fichtlscherer, S. (2006) · Endothelium · doi:10.1080/10623320601061862 · Cited by 138
Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Kandelouei, T., Abbasifard, M., Imani, D., Aslani, S., Razi, B., Fasihi, M., Shafiekhani, S., Mohammadi, K., Jamialahmadi, T., Reiner, Ž., et al. (2022) · Mediators of Inflammation · doi:10.1155/2022/8732360 · Cited by 136
High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus
Firooz, N., Albert, D. A., Wallace, D., ISHIMORI, M. L., Berel, D., & Weisman, M. H. (2011) · Lupus · doi:10.1177/0961203310393378 · Cited by 137
C-Reactive Protein: The Quintessential Marker of Systemic Inflammation in Coronary Artery Disease—Advancing toward Precision Medicine
Amezcua-Castillo, E., González‐Pacheco, H., Martín, A. S.-S., Méndez-Ocampo, P., Gutiérrez-Moctezuma, I., Massó, F., Sierra‐Lara, D., Springall, R., Rodrı́guez, E., Arias‐Mendoza, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11092444 · Cited by 152
Depression, C-reactive Protein and Two-year Major Adverse Cardiac Events in Men after Acute Coronary Syndromes
Frasure‐Smith, N., Lespérance, F., Irwin, M. R., Sauvé, C., Lespérance, J., & Théroux, P. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.029 · Cited by 134
Effect of Pay-for-Performance Incentives on Quality of Care in Small Practices With Electronic Health Records
Bardach, N. S., WANG, J. J., Leon, S. F. D., Shih, S. C., Boscardin, W. J., Goldman, L., & Dudley, R. A. (2013) · JAMA · doi:10.1001/jama.2013.277353 · Cited by 133
Traditional Chinese medication for cardiovascular disease
Hao, P., Jiang, F., Chen, Y., Yang, J., Zhang, K., Zhang, M., Zhang, C., Zhao, Y., & Zhang, Y. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.177 · Cited by 133
The Influence of Anti-Infective Periodontal Treatment on C-Reactive Protein: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Demmer, R. T., Trinquart, L., Zuk, A. M., Fu, B. C., Blomkvist, J., Michalowicz, B. S., Ravaud, P., & Desvarieux, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077441 · Cited by 138
Safety and Efficacy of Remote Ischemic Preconditioning in Patients With Severe Carotid Artery Stenosis Before Carotid Artery Stenting
Zhao, W., Meng, R., Ma, C., Hou, B., Jiao, L., Zhu, F., Wu, W., Shi, J., Duan, Y., Zhang, R., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024807 · Cited by 134
CRP and the risk of atherosclerotic events
Calabrò, P., Golia, E., & Yeh, E. T. H. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0149-4 · Cited by 134

Authors: Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Ridker, Paul M
Cannon, Christopher P.
Morrow, David
Rifai, Nader
Rose, Lynda M.
Pfeffer, Marc A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2005-01-06
Volume: 352
Issue: 1
Pages: 20-28
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa042378
OpenAlex: W2118154631
Cited by: 2,292
References: 28
Citations by year: 2026: 32 · 2025: 46 · 2024: 47 · 2023: 52 · 2022: 70 · 2021: 58 · 2020: 74 · 2019: 64 · 2018: 72 · 2017: 54 · 2016: 78 · 2015: 62 · 2014: 67 · 2013: 93 · 2012: 88
FWCI: 282.76
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: C-reactive protein, statin therapy, LDL cholesterol, atorvastatin, pravastatin, acute coronary syndrome, reinfarction, coronary death, cardiovascular risk, lipid-lowering targets
MeSH terms: Atorvastatin, Gatifloxacin, Anticholesteremic Agents, C-Reactive Protein, Coronary Disease, Female, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Pyrroles, Risk Factors, Biomarkers, Incidence, Proportional Hazards Models, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Fluoroquinolones, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

C-Reactive Protein Levels and Outcomes after Statin Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks